Related Experiment Video
Updated: Jun 25, 2025
Comprehensive Echocardiographic Assessment of Right Ventricle Function in a Rat Model of Pulmonary Arterial Hypertension
Published on: January 20, 2023
Evaluation of mavacamten in patients with hypertrophic cardiomyopathy
Hui-Ling Liao1, Yi Liang2, Bo Liang3
1The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou.
Insights
Mavacamten shows significant efficacy in treating hypertrophic cardiomyopathy (HCM) by improving patient outcomes and reducing key cardiac indicators. While generally safe, it was associated with an increase in adverse events and reduced ejection fraction in some patients.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Hypertrophic cardiomyopathy (HCM) is a genetic heart muscle disease characterized by thickening of the heart muscle.
- Current treatment options for HCM aim to alleviate symptoms and improve quality of life.
Purpose of the Study:
- To conduct a systematic review and meta-analysis assessing the safety and efficacy of mavacamten in patients with HCM.
- To evaluate the impact of mavacamten on clinical outcomes, safety events, and cardiac biomarkers.
Main Methods:
- Systematic review and meta-analysis of four randomized controlled trials (EXPLORER-HCM, VALOR-HCM, MAVERICK-HCM, EXPLORER-CN).
- Evaluation of efficacy parameters including LVOT gradient, LVEF, pVO 2, KCCQ CSS, and NYHA functional class.
- Assessment of safety through adverse events, SAEs, and cardiac biomarkers (NT-proBNP, cTnI).
Main Results:
- Mavacamten significantly reduced postexercise LVOT gradient and improved pVO 2, KCCQ CSS, and NYHA functional class.
- A statistically significant increase in adverse events and a reduction in LVEF to below 50% were observed.
- Mavacamten demonstrated a significant decrease in NT-proBNP and cTnI levels.
Conclusions:
- Mavacamten exhibits both safety and efficacy in HCM patients, indicating its potential as a therapeutic agent.
- Further research is recommended to validate these findings and investigate long-term effects.
Aims:
We aimed to comprehensively assess the safety and efficacy of mavacamten in hypertrophic cardiomyopathy (HCM) patients.
Methods:
A systematic review and meta-analysis was conducted, and efficacy [changes in postexercise left ventricular outflow tract (LVOT) gradient, left ventricular ejection fraction (LVEF), peak oxygen consumption (pVO 2 ), Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ CSS), and the proportion of patients exhibiting an improvement of at least one New York Heart Association (NYHA) functional class from baseline)], safety (total count of treatment-emergent adverse events and SAEs, as well as the proportion of patients experiencing at least one adverse event or SAE), and cardiac biomarkers (NT-proBNP and cTnI) outcomes were evaluated.
Results:
We incorporated data from four randomized controlled trials, namely EXPLORER-HCM, VALOR-HCM, MAVERICK-HCM, and EXPLORER-CN. Mavacamten demonstrated significant efficacy in reducing the postexercise LVOT gradient by 49.44 mmHg ( P = 0.0001) and LVEF by 3.84 ( P < 0.0001) and improving pVO 2 by 0.69 ml/kg/min ( P = 0.4547), KCCQ CSS by 8.11 points ( P < 0.0001), and patients with at least one NYHA functional class improvement from baseline by 2.20 times ( P < 0.0001). Importantly, mavacamten increased 1.11-fold adverse events ( P = 0.0184) 4.24-fold reduced LVEF to less than 50% ( P = 0.0233) and 1.06-fold SAEs ( P = 0.8631). Additionally, mavacamten decreased NT-proBNP by 528.62 ng/l ( P < 0.0001) and cTnI by 8.28 ng/l ( P < 0.0001).
Conclusion:
Mavacamten demonstrates both safety and efficacy in patients with HCM, suggesting its potential as a promising therapeutic strategy for this condition. Further research is warranted to confirm these results and explore its long-term effects.
More Related Videos
07:02Operating Transverse Aortic Constriction with Absorbable Suture to Obtain Transient Myocardial Hypertrophy
Published on: September 9, 2020
03:45Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
